Nexfarm Ibandronate Injection (Ibandronic Acid Sodium Hydrate)
Ibandronate Sodium Monohydrate 3.375mg
Injections · Prescription medication
Nexfarm Korea Co., Ltd.
MFDS item code 201701085 · Notified 2017.02.28 · Insurance code 649103381,662505191
Treatment of osteoporosis in postmenopausal women
This medication is used for the treatment of osteoporosis in postmenopausal women. It helps to increase bone density, strengthen bones, and reduce the risk of fractures.
Administer 3mg by intravenous injection over 15-30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment: No dose adjustment is necessary. No dose adjustment is necessary in patients with mild or moderate renal impairment with a serum creatinine of 200µmol/L(2.3mg/dL) or less or a creatinine clearance of 30ml/min or greater. Because clinical experience is insufficient in patients with a serum creatinine greater than 200µmol/L(2.3mg/dL) or a creatinine clearance below 30ml/min, use of this medicine is not recommended. Older adults: No dose adjustment is necessary.
Children 18 years of age or younger: Efficacy and safety have not been studied.
This medication must be administered intravenously, and caution should be exercised as tissue damage may occur if administered intra-arterially or around the vein. It should not be used in patients with known hypersensitivity to this drug or its components, or in patients with untreated hypocalcemia. Gastric-related symptoms such as gastritis, diarrhea, abdominal pain, indigestion, nausea, and constipation may occur while taking this medication, as well as musculoskeletal pain such as myalgia and arthralgia. Some patients may experience influenza-like symptoms, fatigue, headache, and rash, typically of mild to moderate severity, and recovery occurs without discontinuation of treatment. Adequate intake of calcium and vitamin D is important while using this drug, and supplements should be taken if there is a deficiency. Serious side effects such as osteonecrosis of the jaw have been reported, especially in cancer patients or those taking certain medications; a thorough examination of oral health before dental treatment is recommended, and excessive dental procedures should be avoided during treatment. Additionally, very rarely, serious adverse reactions such as osteonecrosis of the outer ear, severe allergic reactions, skin reactions, and atypical fractures may occur; report any unusual symptoms to healthcare providers immediately. This drug is not metabolized by the liver and is primarily excreted through the kidneys, so patients with impaired kidney function should undergo regular examinations, and monitoring of kidney and liver function should be increased in cases of overdose. Safety during pregnancy or lactation has not been established, so its use is not recommended. This drug should not be mixed with other calcium-containing solutions and used syringes and needles should not be reused but safely discarded. Lastly, the effects on driving or operating machinery are unknown, so caution is advised.
Gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reactions, thrombophlebitis, hypersensitivity reactions, angioedema, facial swelling/edema, hives, osteonecrosis of the jaw and external ear, uveitis, episcleritis, scleritis, anaphylactic reactions/shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical femoral shaft and intertrochanteric fractures, atypical fractures of the iliac bone, dizziness, optic atrophy, lower motor neuron lesions, tremor, unspecified gastrointestinal disorders, benign gastrointestinal tumors, toothache, hyperventilation, cough, dyspnea, laryngitis, vaginitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urinary disorders, hematuria, skin exfoliation, sensory impairment, acute renal failure
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent exposure to air or moisture, ideally at room temperature between 1 and 30 degrees Celsius. Proper storage helps to maintain the effectiveness and safety of the drug.
A colorless, transparent solution in a colorless, transparent glass pre-filled syringe with a single-use injection needle attached.
3ml/pre-filled syringe X 1
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ibandronate Sodium Monohydrate 3.375mg
Injections · Prescription medication
Nexfarm Korea Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.
Ibandronate Sodium Monohydrate 3.375mg
Solution · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Chodang Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Ajou Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.